Towards a sustainable, healthy future for everyone: EU project INHERIT offers policy solutions Today, on 10 December a policy toolkit will be presented at the final conference of the European four-year research project INHERIT.
Prevention essential theme State of Zoonotic Diseases 2018 The focus of our annual report State of Zoonotic Diseases 2018 is prevention, with the emphasis on the production chains of foods of animal origin.
Report on the developments of the National Immunisation Programme: stabilisation of participation and low level of disease In the first six months of 2019, the number of notified meningococcal serogroup W (MenW) disease cases decreased in almost all age groups, after a continuous increase since 2015.
Temporary background values for PFAS in Dutch soil RIVM has derived temporary background values for two types of PFAS in Dutch soil: PFOS (perfluorooctane sulfonate) and PFOA (perfluoro octanoic acid).
Reactor shut down will cause global medical isotope shortage Shutting down the current Dutch reactor which produces medical isotopes, without replacing it, puts the world’s supply of medical radio-isotopes at risk.
National Heat Plan no longer in effect as of July 29th As of Monday, 29 July, the National Heat Plan is no longer in effect. The Heat Plan had been active from July 23rd until July 28th. Never before has it been as hot as last week in the Netherlands.
Tick found in Drenthe is a Hyalomma tick RIVM has investigated the so-called giant tick that was found in Odoorn in the province of Drenthe on 13 July. It is a Hyalomma marginatum female.
National Heat Plan active throughout the Netherlands It is forecasted to be exceptionally hot over the coming days. Temperatures will rise to tropical levels. This can lead to problems for people with vulnerable health.
New standard for exposure assessment of cleaning products RIVM has updated the standard for exposure assessment of cleaning products in the ConsExpo Cleaning Products Fact Sheet.
Off-label use of medicines: Room for improvement Medicinal products may be prescribed for other diseases, or groups of patients, than the ones that they are approved for.